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Abstract
Duchenne muscular dystrophy (DMD) is a devastating primary muscle disease with pathological 
changes in skeletal muscle that are ongoing at birth. Progressive deterioration in striated muscle 
function in affected individuals ultimately results in early death due to cardio-pulmonary failure. 
Since affected individuals can be identified prior to birth by prenatal genetic testing for DMD, 
gene replacement treatment could be started in utero. This approach offers the possibility of 
preventing pathological changes in muscle that begin early in life. To test in utero gene transfer 
utilizing the AAV8 vector in the mdx mouse model of DMD, a minidystrophin gene driven by the 
human cytomegalovirus promoter was delivered systemically by intraperitoneal injection to the 
fetus at embryonic day 16. Treated mdx mice studied at 9 weeks after birth demonstrated 
widespread expression of recombinant dystrophin in skeletal muscle, restoration of the dystrophin 
associated glycoprotein complex in dystrophin-expressing muscle fibers, improved muscle 
pathology, and functional benefit to the transduced diaphragm compared to untreated littermate 
controls. These results support the potential of the AAV8 vector to efficiently cross the blood 
vessel barrier to achieve systemic gene transfer to skeletal muscle in utero in a mouse model of 
muscular dystrophy, to significantly improve the dystrophic phenotype and to ameliorate the 
processes that lead to exhaustion of skeletal muscle regenerative capacity.
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Duchenne muscular dystrophy (DMD) is an X-linked recessive muscle disorder affecting 1 
in 3500 live male births.1 The disease is characterized by progressive loss of muscle 
function leading to premature death, most commonly caused by cardiac and respiratory 
failure.2 Although improvements in medical management and treatment with 
glucocorticoids have significantly improved life expectancy and the quality of life of DMD 
patients, a specific treatment addressing the genetic defect causing DMD is not yet clinically 
available. A crucial challenge of DMD therapeutic research is to develop approaches with 
functional benefit to widespread muscle tissues. Preclinical gene replacement therapy has 
shown promising results in postnatal dystrophic mice3–6 and dogs7,8 although widespread 
gene delivery often requires large vector doses and issues of immunity induced by viral 
vectors remain.
Among gene delivery vectors, adeno-associated viral (AAV) vectors hold great promise for 
gene therapy because of their safety, low toxicity and stable transgene expression.9 In 
particular, AAV serotype 8 (AAV8) vectors demonstrate robust muscle transduction after 
systemic delivery to postnatal mice and hamsters.10,11 However, there are very few studies 
testing gene delivery and functional efficacy of therapeutic transgenes carried by AAV8 
vectors in dystrophic animal models.12
In utero gene delivery for muscle gene replacement therapy offers several advantages. 
Compared to gene delivery later in life, gene transfer to the fetus provides an opportunity to 
target a higher percentage of cells when the tissue mass is small. In humans, myotube 
formation is observed between gestation weeks 7 and 14 and by week 20, muscle fibers are 
arranged in discrete bundles.13 In mice, secondary myotubes begin to form on the scaffold 
of the primary myotubes from embryonic day 14 (E14) to E17.14–19 Therefore, most murine 
in utero muscle gene delivery studies have been performed at E15 or E16 when secondary 
myotubes are forming.
For genetic diseases such as DMD where the clinical signs and symptoms are often not 
detected until affected children are 2–5 years old, fetal DNA diagnostics and gene transfer in 
utero provide a unique opportunity to treat at the earliest stage of the disease. The 
immaturity of the basal lamina may play an important role in widespread gene delivery to 
fetal muscle.20,21 Finally, the minimal transduction of liver by AAV8 vectors when 
delivered systemically in utero is a desirable outcome of muscle-targeted gene delivery and 
limits the possibility of liver toxicity from gene delivery.22
Since most primary muscle disorders affect multiple muscle groups including the 
diaphragm, an important challenge for muscle gene therapy is to achieve transgene 
expression in widespread muscle tissues. In our previous study of the biodistribution of an 
AAV8 vector carrying the lacZ gene after systemic administration in utero, we 
demonstrated successful widespread gene expression in various muscle tissues including 
high levels of expression in diaphragm and intercostal muscles.22 This biodistribution study 
suggested that AAV8 could be an ideal vector for the treatment of primary muscle disorders 
in utero. Therefore, we explored the therapeutic potential of an AAV8 vector carrying a 
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minidystrophin gene when delivered systemically in utero to the dystrophic mdx mouse 
model of DMD.
MATERIALS AND METHODS
Production of AAV8 minidystrophin vector
The cloning and construction of the canine minidystrophin cDNA has been previously 
described.23 Briefly, the AAV8 vector carrying a canine minidystrophin expression cassette 
driven by the human cytomegalovirus (HCMV) promoter (AAV8 minidystrophin) was 
generated by the triple-plasmid transfection method using 3 plasmids comprising the AAV-
CMV-minidystrophin vector plasmid, the mini-adeno helper plasmid, and the AAV8 
packaging plasmid containing the AAV2 Rep gene and AAV8 Cap gene, as described 
previously.24,25 AAV8 minidystrophin viral particles were purified by double CsCl gradient 
centrifugation and dialyzed 3 times against PBS containing 5% sorbitol. The titer of vector 
genomes (vg) was determined by a standard DNA dot-blot assay.
In utero administration of AAV8 minidystrophin vector
AAV8 minidystrophin was administered intraperitoneally in utero into E16 pups of timed 
pregnant mdx female mice as described previously22 according to a protocol approved by 
the University of Pittsburgh Institutional Animal Care and Use Committee. The vector was 
injected at a dose of 6.4 × 1011 vg/pup. In order to identify the injected pup, a fluorescent 
marker, 2% orange fluorescent FluoSpheres (Invitrogen, Carlsbad, CA, USA), was injected 
into one of the limbs permitting identification of injected pups several days after birth by 
observation under a fluorescent microscope. The vector-treated mice were analyzed at 9 
weeks of age in parallel with age-matched untreated mdx littermate and C57BL/10 controls.
Ex vivo functional analysis of diaphragm
Ex vivo functional analysis was performed on diaphragm 9 weeks after birth following in 
utero treatment with AAV8 minidystrophin vector. Diaphragm specific force (peak 
isometric tetanic force normalized for muscle cross-sectional area) and force generation 
during repetitive isovelocity lengthening activations were performed as previously 
described.26 Analysis of variance with Tukey’s post hoc test for multiple comparisons was 
used to identify statistical differences between groups with respect to specific force and 
residual force following lengthening activations (P<0.05).
Histology and Immunohistochemistry
Muscle samples were snap frozen and sectioned using a cryostat. To assess morphology, 
sections were stained with hematoxylin and eosin (H&E). For immunohistochemistry, the 
sections were blocked with 2% bovine serum albumin and washed with phosphate-buffered 
saline 3 times after each step. Immunostaining for α-sarcoglycan and β-dystroglycan was 
performed as described previously.27,28 For dystrophin staining, sections were incubated 
with a rabbit anti-dystrophin antibody (Invitrogen, Eugene, OR, USA) at a dilution of 1:800, 
followed by AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Inc., West 
Grove, PA, USA) at a dilution of 1:1000. Cell nuclei were stained with Hoechst dye. 
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Uninjected mdx littermate and C57BL/10 normal muscles were used as negative and 
positive controls, respectively, for immunostaining.
Quantification of fibers with centrally-placed nuclei
Muscle sections stained for dystrophin and Hoechst dye were counted to score the number 
of fibers with centrally-placed nuclei in dystrophin positive and dystrophin negative fibers in 
muscle sections from treated mice. A similar analysis of uninjected mdx littermates and 
C57BL/10 mice was performed for disease and normal controls, respectively. The 
percentage of fibers with centrally-placed nuclei was than calculated from analysis of 
approximately 300 muscle fibers in randomly selected fields. Analysis of variance with 
Tukey’s post hoc test for multiple comparisons was used to identify statistical differences 
between groups (P<0.05).
Analysis of vector genomes by real time PCR
Total DNA was isolated from the muscle tissues of treated and untreated mdx and C57BL/10 
mice by ethanol precipitation (Wizard genomic DNA purification kit, Promega, Madison, 
WI, USA) and the vector genomes calculated as described previously.22 PCR primers for the 
minidystrophin gene had the following sequence: forward primer: 
CACCCATAAGGAAAGGCTTCTAGAA and reverse primer: 
GAGATCTTGCCATTGTTTCATCAG. The TaqMan probe sequence was: 
ATTCCAAGGGAGTAAGAGA. The results were presented as copies of vector particles 
per 1000 nuclei.
RESULTS
Expression of recombinant dystrophin and improvement in muscle morphology after 
intraperitoneal administration of AAV8 minidystrophin in utero
A dose of 6.4 × 1011 vg of an AAV8 vector carrying a canine mini-dystrophin cDNA driven 
by the HCMV promoter was injected intraperitoneally per fetus on E16. Pups were delivered 
naturally at full term. At 9 weeks of age, experimental mice were sacrificed and diaphragm, 
upper limb, and lower limb muscles were collected from the injected pups and the 
uninjected littermates. To assess the gene transfer efficiency, cryosections of these tissues 
were analyzed for expression of dystrophin (Figure 1). The treated diaphragm exhibited the 
highest level of transgene expression. Limb muscles also demonstrated widespread 
dystrophin expression, while in the control mdx muscles we observed only rare revertant 
dystrophin positive fibers.
The dystrophic change of untreated mdx muscle tissue at 9 weeks of age is characterized by 
necrotic and regenerating muscle fibers, a mononuclear cell infiltrate and increased fibrous 
connective tissue. To evaluate the histology of muscle tissues, cryosections of diaphragm, 
upper limb and lower limb muscles collected from the injected pups at 9 weeks of age were 
stained with H&E. The treated muscles showed decreased fiber size variability, less 
mononuclear cellular infiltration, and reduced fibrosis compared to untreated mdx controls 
(Figure 1). Together, the morphological findings suggest skeletal muscle benefit from 
expression of recombinant dystrophin delivered by an AAV8 vector in utero to mdx mice.
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Restoration of dystrophin-associated glycoprotein (DAG) complex in muscle after 
intraperitoneal administration of AAV8 minidystrophin in utero
The absence of dystrophin expression in mdx muscle disrupts the structural link between 
cytoplasmic actin filaments and the sarcolemmal DAG complex leading to the dysfunction 
and/or loss of the DAG complex from the sarcolemma. Dystrophin protein functions in 
conjunction with the DAG complex.29,30 Hence, we studied whether in utero gene transfer 
of an AAV8 vector carrying minidystrophin can restore the DAG complex. At 9 weeks of 
age the diaphragm, the upper limb, and the lower limb muscles from the injected pups, and 
the uninjected littermates were analyzed for α-sarcoglycan and β-dystroglycan expression. 
Expression of α-sarcoglycan and β-dystroglycan was restored in fibers expressing 
recombinant dystrophin (Figure 2) suggesting functional benefit of AAV8 vector-mediated 
minidystrophin gene delivery in utero to mdx mice.
Decreased percentage of fibers harboring centrally-placed nuclei in muscle after 
intraperitoneal administration of AAV8 minidystrophin in utero
Cycles of degeneration and regeneration of muscle fibers result in the accumulation of 
muscle fibers harboring centrally-placed nuclei.31,32 To characterize the degree of this 
pathological process we calculated the percentage of muscle fibers with centrally-placed 
nuclei in mdx untreated fibers, AAV8 minidystrophin treated, dystrophin-positive fibers, 
AAV8 minidystrophin-treated, dystrophin-negative fibers, and C57BL/10 fibers in 
diaphragm and hindlimb muscles of 9-week-old mice (Figure 3). We observed a high 
percentage of fibers with centrally-placed nuclei in untreated mdx diaphragm (62.6% ± 4.7) 
and hindlimb muscle (71.8% ± 4.6), while C57BL/10 muscle showed very few fibers with 
centrally-placed nuclei in the diaphragm and hindlimb (1.1% ± 0.7 and 1.3% ± 0.5, 
respectively). The percentage of fibers with centrally placed nuclei in dystrophin-expressing 
fibers of AAV8 minidystrophin treated mdx mice was significantly less (P < 0.05) in 
diaphragm and hindlimb (21.7% ± 2.4 and 26.7% ± 2.7, rrespectively) compared to 
untreated control mdx mice. The improvements in mdx muscle pathology observed after 
AAV8 minidystrophin treatment in utero are indications of its potential benefit in a 
muscular dystrophy animal model.
Improvement of ex vivo functional force generation properties of costal diaphragm after 
intraperitoneal administration of AAV8 minidystrophin in utero
To test whether widespread expression of minidystrophin in costal diaphragm could provide 
functional improvement, the force properties of treated mdx diaphragm, untreated mdx 
diaphragm and C57BL/10 control diaphragm were tested and compared. Nine weeks after 
birth, costal diaphragm was collected for ex vivo force measurements. Diaphragm specific 
force (peak isometric tetanic force normalized for muscle cross-sectional area) and force 
generation during repetitive isovelocity lengthening activations were performed as 
previously described.26 AAV8 minidystrophin-treated diaphragm exhibited a statistically 
significant (P < 0.05) 32.6% increase in specific force compared to paired littermate 
untreated mdx diaphragm [mdx untreated (n=11 mice): 14.7 ± 3.0 N/cm2; mdx treated (n=6 
mice): 19.5 ± 1.5 N/cm2; C57BL/10 control (n=5 mice) 21.1 ± 2.7] (Figure 4a). Specific 
force of AAV8 minidystrophin-treated diaphragm approximated (statistically insignificant 
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difference) that seen in age-matched C57BL/10 wild-type controls. After determining peak 
tetanic force the diaphragm was subjected to repetitive lengthening activations, a paradigm 
of mechanical stress.33 Residual diaphragm force following 10 repetitive lengthening 
activations, expressed as a percent of initial, was significantly greater in AAV8 
minidystrophin-treated diaphragm than untreated littermate paired mdx diaphragm [mdx 
untreated (n=11 mice): 84.5 ± 5; mdx treated (n=6 mice): 99 ± 7.6; C57BL10 control (n=5 
mice): 101 ± 7.1] (Figure 4b). These data demonstrate that AAV8 minidystrophin delivered 
systemically in utero provides significant functional improvements in the dystrophic mdx 
diaphragm as demonstrated by specific force generation and the ability to withstand 
eccentric muscle contraction.
Quantification of AAV vector genomes in muscle tissues after intraperitoneal 
administration of AAV8 minidystrophin in utero
To determine viral vector gene transfer efficiency and compare with the previous marker 
gene study in normal mice, we quantified the number of viral particles in individual tissues 
by real time PCR. The highest levels of viral vector particles were observed in diaphragm. 
Diaphragm had 227.77 ± 85.07 viral particles per 1000 nuclei respectively. Upper and lower 
limbs had 38.70 ± 22.59 and 33.90 ± 13.82 viral particles per 1000 nuclei respectively. 
These findings are similar to and confirm our previous study in normal mice in whom a 
similar dose of AAV8 carrying a lacZ gene was delivered by the same route in utero.22 The 
results thus demonstrate the efficacy of AAV8 minidystrophin to successfully deliver the 
therapeutic gene into dystrophic muscle tissues that was comparable to gene delivery to 
normal muscle tissue.
DISCUSSION
This study demonstrates the potential of fetal gene therapy to correct a genetic defect that is 
lethal in humans, in a preclinical model. Other disorders where preclinical fetal gene transfer 
studies have shown partial correction of a genetic defect include mucopolysaccharidosis 
type VII,34,35 Crigler-Najjar Syndrome Type 1,36α-thalassemia,37 hemophilia B,38 cystic 
fibrosis,39 and Pompe disease.40 In this study, the improvements in muscle pathology, which 
are also reflected in functional benefit in the diaphragm, suggest that dystrophin gene 
transfer in utero for the treatment of dystrophin deficiency has the potential to preserve 
muscle regenerative capacity by gene replacement at this very early stage.
This study demonstrates the ability of AAV8 to systemically transduce widespread muscles, 
including the diaphragm and therapeutic benefit in a DMD model in utero. Although we also 
achieved in utero dystrophin gene delivery in mdx mice with an adenoviral vector,21 the 
AAV8 vector provides markedly more evidence of morphological and functional benefit. 
One limitation of the AAV8 vector for the treatment of DMD in utero, however, is a low 
level of cardiac transduction.22 Another serotype of AAV, AAV9, offers higher levels of 
cardiac transduction when delivered postnatal,10 but has not been tested for in utero gene 
delivery.
Most previous muscle gene transfer studies with AAV8 have been performed in postnatal 
animals and showed that the AAV8 vector efficiently transduces muscle tissues of neonatal 
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and adult animals. In a study of multiple AAV vector serotypes, Wang et al. showed that 
AAV8 was systemically delivered efficiently to muscle in neonatal and adult mice.11 
Similarly, Inagaki et al. showed robust transduction of muscle tissue following systemic 
delivery of various doses of AAV8 vector in adult mice.10 Zincarelli et al. observed that tail 
vein injection of an AAV8-luciferase vector into 6–8 week old mice not only showed 
persistent transgene expression for at least 100 days, but also demonstrated uniform 
expression of luciferase in hindlimb, abdominal and thoracic regions.41
The biodistribution of AAV8 when delivered in utero was shown in our previous study of 
AAV8 gene delivery in utero. Intraperitoneal delivery of an AAV8 vector carrying a lacZ 
gene to fetal mice in utero resulted in widespread postnatal gene expression in multiple 
muscle tissues, including diaphragm, intercostal muscles, forelimb and hindlimb muscles 
with the highest expression seen in the diaphragm and intercostal muscles.22
Encouraged by these results with gene delivery of a marker gene in utero using an AAV8 
vector, we performed the present in utero gene transfer study in a muscular dystrophy model 
with a therapeutic transgene and demonstrated for the first time that an AAV8 vector 
carrying a minidystrophin gene injected systemically in utero could restore muscle structure 
and function. The AAV8 vector carrying a mindystrophin gene was injected 
intraperitoneally into E16 mdx pups and muscle was analyzed 9 weeks after birth. We 
observed efficient transduction and restoration of dystrophin in diaphragm, forelimb and 
hindlimb muscles. In addition, immunostaining of the transduced muscles demonstrated 
restoration of the DAG complex, evidenced by expression of α-sarcoglycan and β-
dystroglycan at the sarcolemma of those fibers expressing recombinant dystrophin.
Mdx muscle tissues undergo degeneration evidenced pathologically by necrosis and 
regeneration. The degree of regeneration is proportional to the percentage of fibers 
harboring centrally-placed nuclei. In this study we observed that the dystrophin-expressing 
fibers in treated muscle had significantly fewer centrally-placed nuclei compared to muscle 
fibers of untreated mdx mice. This finding suggested that recombinant dystrophin provided 
by systemic gene delivery in utero partially protected transduced muscle fibers from cycles 
of degeneration and regeneration. Furthermore, in treated mdx muscle, even among the 
fibers where recombinant dystrophin was not detected, there was a non-significant decrease 
in the number of fibers with centrally-placed nuclei compared to muscle of untreated mdx 
mice. It is possible that despite absence of immunohistochemical detection of dystrophin 
expressed by these fibers, dystrophin expression may have been present at a level below the 
detection threshold and may have provided functional benefit. Alternatively, there may be a 
‘bystander’ benefit to non-transduced fibers or non-transduced regions of fibers from being 
in a treated muscle in close proximity to fibers and fiber segments that express recombinant 
dystrophin. Therefore, a significant potential benefit of in utero muscle gene transfer for 
DMD may be to reduce the degree of exhaustion of the satellite cell pool by achieving gene 
transfer early.
To date, AAV8 has successfully provided therapeutic benefit to skeletal muscle in two 
disease models in prior postnatal studies. Ziegler et al. showed that systemic administration 
of an AAV8 vector carrying the human acid α-glucosidase (GAA) gene to 2 month old 
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presymptomatic GAA-deficient mice that model Pompe disease resulted in nearly complete 
correction of the lysosomal storage of glycogen in all the affected muscles.42 Another study 
also demonstrated correction of GAA deficiency in muscle tissue of immunodeficient GSD-
II mice by treatment with an AAV8 vector.43 In another muscle disease model, systemic 
delivery of an AAV8 vector carrying a myostatin inhibitor in adult mdx mice enhanced 
muscle growth and also ameliorated the dystrophic phenotype.44
Only one previous study reported on AAV gene transfer in utero for treatment of a muscle 
disease. In a mouse model of Pompe disease, an AAV2 vector carrying the α-glucosidase 
gene was delivered intraperitoneally in utero and resulted in improvement in diaphragmatic 
in vitro isometric force-frequency studies 6 months after birth40 However, AAV8 has not 
been previously reported in therapeutic gene delivery studies in utero in a preclinical model 
of a muscle disease.
In postnatal gene delivery studies, restoration of dystrophin expression has been correlated 
with muscle functional benefit after AAV8 gene delivery. In a study involving AAV8 
carrying microdystrophin delivered systemically into the femoral artery in 3 – 4 week old 
mdx mice and non human primates, significant improvement in tetanic force and protection 
against eccentric contraction in the EDL muscle was shown.12 Since dystrophic patients 
usually die due to respiratory and cardiac failure,2 restoring dystrophin expression to the 
diaphragm, which plays a critical role in respiration and survival, will be highly important to 
DMD patients. In the study reported here, the diaphragm was collected 9 weeks following 
birth for ex vivo force measurements. AAV8 minidystrophin treated diaphragm exhibited a 
32% improvement in specific force compared to diaphragms from untreated mdx littermates. 
In normal muscle, dystrophin provides resistance against contraction induced injury. We 
observed that the residual force generated following 10 repetitive lengthening activations 
was significantly improved by AAV8 minidystrophin gene delivery in utero compared to 
untreated mdx diaphragm.
In summary, systemic delivery of minidystrophin with an AAV8 vector in utero provides 
efficient transduction of diaphragm and limb muscles of the mdx mouse when studied after 
birth. The functional benefit demonstrated in transduced diaphragm muscle encourages 
further studies to test the persistence of vector expression and in utero gene delivery in large 
animal models of DMD.
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Figure 1. Restoration of dystrophin and amelioration of dystrophic pathology in AAV8 
minidystrophin treated mdx diaphragm, upper limb and lower limb muscles
Tissues were collected at 9 weeks after birth following an intraperitoneal injection of AAV8 
minidystrophin into E-16 pups of pregnant mdx mice and analyzed for dystrophin 
expression. Dystrophin immunohistochemistry (upper panels) and H & E staining (lower 
panels) were evaluated in (a) diaphragm, (b) upper limb, and (c) lower limb muscles. 
Uninjected mdx littermates and C57BL/10 tissues were used as negative and positive 
controls, respectively, for immunohistochemistry and histology. Dys, dystrophin; α-SG, α-
sarcoglycan; β-DG, β-dystroglycan. H&E, hematoxylin and eosin. Bar = 100 μm.
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Figure 2. Restoration of dystrophin associated glycoprotein (DAG) complex proteins in lower 
limb muscle sections after in utero gene transfer of AAV8 minidystrophin
Gastrocnemius muscle from mice treated with AAV8 minidystrophin at E16 in utero at a 
dose of 6.4 × 1011 vector genomes per fetus was cryosectioned. Staining of serial sections 
with hematoxylin and eosin (H&E) and immunohistochemistry for dystrophin, α-
sarcoglycan (α-SG) and β-dystroglycan (β-DG) are shown. Bar = 100 μm.
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Figure 3. Decreased percentage of fibers with centrally placed nuclei associated with 
recombinant minidystrophin expression in muscle tissues after intraperitoneal administration of 
AAV8 minidystrophin vector in utero
The percentage of fibers with centrally-placed nuclei was calculated from cross-sections of 
(a) diaphragm and (b) lower limb muscles treated by systemic in utero delivery of an AAV8 
minidystrophin vector at E16 at a dose of 6.4 × 1011 vector genomes per fetus. Fibers from 
the C57BL/10 normal mice, the untreated mdx, and the treated dystrophin positive and 
dystrophin negative mdx, were analyzed. The data is shown as mean ± SE. Significant 
differences from untreated mdx mice are shown (*P<0.05). dys, dystrophin.
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Figure 4. Improvement in force generation properties in diaphragm after intraperitoneal 
administration of AAV8 minidystrophin vector in utero
The diaphragm muscles were collected at 9 weeks of age from mice treated in utero and 
were analyzed ex vivo. Diaphragms of control C57BL/10 (n=5 mice), AAV8 minidystrophin 
vector-treated mdx (n=6 mice) and untreated mdx (n=11 mice) mice were analyzed for (a) 
specific force (N/cm2) and (b) residual force following 10 repetitive lengthening activations 
divided by initial force and expressed as a percentage. The data is shown as mean ± SE. 
Significant differences from untreated mdx mice are shown (*P<0.05).
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